EFFECTIVENESS OF RABEPRAZOLE (BERETA) IN THE TREATMENT OF PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE


D.S. Bordin, O.B. Yanova, V.A. Kim

SBHCI "Moscow Clinical Research and Practice Center" of the Moscow Healthcare Department
The evaluation of the efficacy of rabeprazole (Bereta, Veropharm) in the treatment of gastroesophageal reflux disease (GERD) was performed. Twenty-five patients with GERD, including 15 patients with erosive reflux esophagitis (RE), have received rabeprazole at daily dose of 20 mg for 21 days. At the 14th day of treatment, heartburn was arrested in 100%, regurgitation - in 91.7%, belching air - in 76.5% of patients. At the 21st day of treatment, epithelialization of erosions was achieved in 100% of patients with erosive RE. Relief of symptoms was accompanied by a significant improvement in well-being and quality of life of patients.

About the Autors


D.S. Bordin – MD, Head of Division of pathology of the pancreas, biliary tract and upper digestive tract SBHCI MCRPC MHD; tel. +7 (495) 304-95-51
O.B. Yanova – PhD in Medical Sciences, Head of the Department of pathology of the upper gastrointestinal tract SBHCI MCRPC MHD; tel. + 7 (495) 303-17-71
V.A. Kim - PhD in Medical Sciences, Senior Scientist at the Department of visual research methods SBHCI MCRPC MHD; tel. +7 (495) 303-17-71


Similar Articles


Бионика Медиа